XBiotech Company Profile (NASDAQ:XBIT)

About XBiotech (NASDAQ:XBIT)

XBiotech logoXBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XBIT
  • CUSIP: N/A
  • Web: www.xbiotech.com
Capitalization:
  • Market Cap: $168.68 million
  • Outstanding Shares: 35,290,000
Average Prices:
  • 50 Day Moving Avg: $5.05
  • 200 Day Moving Avg: $10.57
  • 52 Week Range: $2.77 - $20.18
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.34 per share
  • Price / Book: 1.98
Profitability:
  • EBIDTA: ($51,970,000.00)
  • Return on Equity: -71.77%
  • Return on Assets: -65.08%
Debt:
  • Current Ratio: 10.73%
  • Quick Ratio: 10.73%
Misc:
  • Average Volume: 469,095 shs.
  • Beta: 0.66
  • Short Ratio: 5.75
 
Frequently Asked Questions for XBiotech (NASDAQ:XBIT)

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How were XBiotech's earnings last quarter?

XBiotech Inc. (NASDAQ:XBIT) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.08. View XBiotech's Earnings History.

When will XBiotech make its next earnings announcement?

XBiotech is scheduled to release their next quarterly earnings announcement on Monday, August, 14th 2017. View Earnings Estimates for XBiotech.

Where is XBiotech's stock going? Where will XBiotech's stock price be in 2017?

2 equities research analysts have issued 12-month target prices for XBiotech's shares. Their predictions range from $13.00 to $13.00. On average, they anticipate XBiotech's share price to reach $13.00 in the next twelve months. View Analyst Ratings for XBiotech.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 5,835,997 shares, an increase of 32.2% from the May 31st total of 4,414,704 shares. Based on an average trading volume of 1,692,449 shares, the short-interest ratio is presently 3.4 days. Currently, 37.4% of the shares of the company are sold short.

Who are some of XBiotech's key competitors?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:

  • John Simard, Chairman of the Board, President, Chief Executive Officer, Founder
  • Scott Whitehurst, Chief Financial Officer
  • Kelly R. Thornburg, Senior Vice President - Operations
  • Queena Han, Vice President - Finance, Human Resources
  • David J Combs, Vice President - Manufacturing
  • Norma I Gonzalez, Vice President - Quality
  • Dawn McCollough, Vice President of Clinical Operations
  • Sushma Shivaswamy, Vice President - Research & Development
  • Michael D Stecher, Medical Director
  • Daniel L. Vasella M.D., Lead Independent Director

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

How do I buy XBiotech stock?

Shares of XBiotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBiotech stock can currently be purchased for approximately $4.63.


MarketBeat Community Rating for XBiotech (NASDAQ XBIT)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  82
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for XBiotech (NASDAQ:XBIT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.00 (180.78% upside)

Analysts' Ratings History for XBiotech (NASDAQ:XBIT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/3/2017Stifel NicolausUpgradeHold -> BuyHighView Rating Details
4/21/2017Noble FinancialReiterated RatingBuy -> Hold$13.00HighView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for XBiotech (NASDAQ:XBIT)
Earnings by Quarter for XBiotech (NASDAQ:XBIT)
Earnings History by Quarter for XBiotech (NASDAQ XBIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017($0.32)N/AView Earnings Details
11/14/2016Q3 2016($0.46)($0.38)ViewListenView Earnings Details
11/12/2015Q3($0.21)($0.33)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for XBiotech (NASDAQ:XBIT)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for XBiotech (NASDAQ:XBIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for XBiotech (NASDAQ:XBIT)
Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 10.13%
Insider Trades by Quarter for XBiotech (NASDAQ:XBIT)
Institutional Ownership by Quarter for XBiotech (NASDAQ:XBIT)
Insider Trades by Quarter for XBiotech (NASDAQ:XBIT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2016Queena HanVPSell19,573$15.00$293,595.00View SEC Filing  
9/8/2016Queena HanVPSell427$15.00$6,405.00View SEC Filing  
5/26/2016W Thorpe MckenzieDirectorBuy20,000$13.96$279,200.00View SEC Filing  
5/20/2016W Thorpe MckenzieDirectorBuy1,500$13.75$20,625.00View SEC Filing  
12/22/2015Queena HanVPSell30,000$10.39$311,700.00View SEC Filing  
11/16/2015Michael StecherDirectorSell1,800$14.00$25,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for XBiotech (NASDAQ:XBIT)
Latest Headlines for XBiotech (NASDAQ:XBIT)
Source:
DateHeadline
finance.yahoo.com logoRobbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - July 12 at 9:28 AM
americanbankingnews.com logoXBiotech Inc. (XBIT) Short Interest Update
www.americanbankingnews.com - June 30 at 7:14 AM
marketwatch.com logoStock market climbs as health-care shares extend rally
www.marketwatch.com - June 22 at 2:50 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Xbiotech and GTx
finance.yahoo.com - June 13 at 8:51 AM
thestreet.com logoBiotech Movers: Coherus, XBiotech, Flexion - TheStreet.com
www.thestreet.com - June 12 at 8:13 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-GE, tech stocks, Coherus, XBiotech - Nasdaq
www.nasdaq.com - June 12 at 8:13 PM
finance.yahoo.com logoBiotech Movers: Coherus, XBiotech, Flexion
finance.yahoo.com - June 12 at 8:13 PM
americanbankingnews.com logoXBiotech Inc (XBIT) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 10 at 11:12 PM
finance.yahoo.com logoXBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis
finance.yahoo.com - June 10 at 3:34 AM
americanbankingnews.com logoZacks: Analysts Set $10.00 Price Target for XBiotech Inc (XBIT)
www.americanbankingnews.com - June 9 at 8:20 PM
americanbankingnews.com logoXBiotech Inc (XBIT) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - June 8 at 7:48 AM
finance.yahoo.com logoWhy XBiotech Inc. (XBIT) Could Shock the Market Soon
finance.yahoo.com - June 7 at 1:16 AM
americanbankingnews.com logoXBiotech Inc (XBIT) Rating Increased to Buy at Stifel Nicolaus
www.americanbankingnews.com - June 3 at 10:40 PM
streetinsider.com logoXBiotech (XBIT) Presents Phase III Findings for Antibody Therapy for Colorectal Cancer at ASCO
www.streetinsider.com - June 3 at 2:35 AM
nasdaq.com logoNotable Thursday Option Activity: XBIT, BOX, PBYI
www.nasdaq.com - June 3 at 2:35 AM
finance.yahoo.com logoWhy XBiotech Inc Jumped Higher Today
finance.yahoo.com - June 3 at 2:35 AM
finance.yahoo.com logoXBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
finance.yahoo.com - June 2 at 7:26 AM
finance.yahoo.com logoDr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer
finance.yahoo.com - May 30 at 8:08 AM
finance.yahoo.com logoDr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Ca...
finance.yahoo.com - May 30 at 8:08 AM
americanbankingnews.com logoXBiotech Inc (XBIT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 20 at 7:08 AM
streetinsider.com logoAfter-Hours Stock Movers 05/18: (SPWH) (ADSK) (MCK) Higher; (XBIT) (HALO) (GSBD) Lower (more...)
www.streetinsider.com - May 19 at 1:52 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
finance.yahoo.com - May 17 at 12:15 AM
americanbankingnews.com logoZacks: Brokerages Expect XBiotech Inc (XBIT) to Post -$0.47 Earnings Per Share
www.americanbankingnews.com - May 12 at 8:14 AM
finance.yahoo.com logoXBiotech No. 2 Executive Resigns, Leaving Struggling Biotech Without Top Operations Chief
finance.yahoo.com - May 11 at 3:18 PM
finance.yahoo.com logoEdited Transcript of XBIT earnings conference call or presentation 4-May-17 12:30pm GMT
finance.yahoo.com - May 11 at 3:36 AM
finance.yahoo.com logoInvestor Network: XBiotech, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 9:29 AM
americanbankingnews.com logoXBiotech (XBIT) Receives Daily News Impact Score of 0.13
www.americanbankingnews.com - May 3 at 4:26 PM
americanbankingnews.com logoXBiotech Inc (XBIT) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 1:52 PM
finance.yahoo.com logoXBiotech to Provide First Quarter 2017 Business Update
finance.yahoo.com - April 29 at 2:40 AM
americanbankingnews.com logoXBiotech (XBIT) Earning Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 28 at 8:34 AM
americanbankingnews.com logoXBiotech (XBIT) Receiving Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 25 at 3:14 PM
americanbankingnews.com logoXBiotech Inc (XBIT) Short Interest Update
www.americanbankingnews.com - April 22 at 5:17 PM
marketwatch.com logoXBiotech's stock plummets after cancer treatment receives disappointing review panel vote
www.marketwatch.com - April 22 at 9:16 AM
streetinsider.com logoXBiotech (XBIT) Announces EMA Negative 'Trend' Vote Related to MAA for Candidate Antibody for Treatment of Colorectal Cancer
www.streetinsider.com - April 22 at 9:16 AM
finance.yahoo.com logoXBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection
finance.yahoo.com - April 21 at 9:51 PM
finance.yahoo.com logoXBiotech Stock Crumbles Following Disappointing EMA Meeting
finance.yahoo.com - April 21 at 9:51 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
finance.yahoo.com - April 21 at 9:51 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.
finance.yahoo.com - April 21 at 9:51 PM
finance.yahoo.com logoXBIOTECH NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm
finance.yahoo.com - April 21 at 9:51 PM
fool.com logoWhy XBiotech Inc. Got Crushed Today
www.fool.com - April 21 at 2:26 PM
americanbankingnews.com logoXBiotech Inc (XBIT) Stock Rating Lowered by Noble Financial
www.americanbankingnews.com - April 21 at 11:27 AM
americanbankingnews.com logoXBiotech (XBIT) Earning Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 9:46 AM
americanbankingnews.com logoZacks: Brokerages Anticipate XBiotech Inc (XBIT) to Post -$0.47 EPS
www.americanbankingnews.com - April 21 at 8:51 AM
finance.yahoo.com logoXBiotech Announces Outcome of EMA's Oral Explanation Meeting
finance.yahoo.com - April 21 at 1:21 AM
americanbankingnews.com logo XBiotech Inc (XBIT) Given $26.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 20 at 3:20 PM
globenewswire.com logoXBiotech Announces Additions To Its Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - April 12 at 8:45 AM
finance.yahoo.com logoXBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About
finance.yahoo.com - April 7 at 1:35 PM
nasdaq.com logoXBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus Infections
www.nasdaq.com - April 4 at 4:51 AM
thestreet.com logo[video]XBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About
www.thestreet.com - April 4 at 4:51 AM
americanbankingnews.com logoZacks: XBiotech Inc (XBIT) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 4 at 12:43 AM

Social

Chart

XBiotech (XBIT) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff